KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Inventory (2016 - 2025)

Historic Inventory for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q4 2025 value amounting to $1.7 billion.

  • Vertex Pharmaceuticals' Inventory rose 3993.7% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 3993.7%. This contributed to the annual value of $1.7 billion for FY2025, which is 3993.7% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Inventory stood at $1.7 billion, which was up 3993.7% from $1.6 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Inventory registered a high of $1.7 billion during Q4 2025, and its lowest value of $298.9 million during Q1 2021.
  • Moreover, its 5-year median value for Inventory was $646.1 million (2023), whereas its average is $780.7 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Inventory skyrocketed by 1339.64% in 2022 and then surged by 7740.86% in 2023.
  • Vertex Pharmaceuticals' Inventory (Quarter) stood at $353.1 million in 2021, then skyrocketed by 30.44% to $460.6 million in 2022, then skyrocketed by 60.4% to $738.8 million in 2023, then soared by 63.16% to $1.2 billion in 2024, then soared by 39.94% to $1.7 billion in 2025.
  • Its Inventory was $1.7 billion in Q4 2025, compared to $1.6 billion in Q3 2025 and $1.5 billion in Q2 2025.